Outcomes related to methotrexate dose and route of administration in patients with rheumatoid arthritis: A systematic literature review

Clinical and Experimental Rheumatology

Volumn 33, Issue 2, 2015, Pages 272-278

  Goodman, Susan M ^a   Cronstein, Bruce N ^b   Bykerk, Vivian P ^b  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Methotrexate; Outcomes; Rheumatoid arthritis; Systematic literature review

Indexed keywords

METHOTREXATE; PLACEBO; IMMUNOSUPPRESSIVE AGENT;

DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RETENTION; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; EVIDENCE BASED MEDICINE; GASTROINTESTINAL SYMPTOM; HUMAN; LONGITUDINAL STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME; VOMITING; ARTHRITIS, RHEUMATOID; BIOAVAILABILITY; DOSE CALCULATION; DRUG ADMINISTRATION; DRUG SELF ADMINISTRATION; IMMUNOLOGY; INFUSION; ORAL DRUG ADMINISTRATION; RISK FACTOR; SUBCUTANEOUS DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ARTHRITIS, RHEUMATOID; BIOLOGICAL AVAILABILITY; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, PARENTERAL; INJECTIONS, SUBCUTANEOUS; METHOTREXATE; RISK FACTORS; SELF ADMINISTRATION; TREATMENT OUTCOME;

EID: 84939558454     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Review

References (82)

1. KATCHAMART W, TRUDEAU J, PHUMETHUM V, BOMBARDIER C: Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis. Cochrane Database Syst Rev 2010 Apr 14; (4): CD008495.
2. PINCUS T, YAZICI Y, SOKKA T, ALETAHA D, SMOLEN JS: Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol 2003; 21 (Suppl. 31): S179-85.
3. PINCUS T, SOKKA T, CHUNG CP, CAWKWELL G: Declines in number of tender and swollen joints in patients with rheumatoid arthritis seen in standard care in 1985 versus 2001: possible considerations for revision of inclusion criteria for clinical trials. Ann Rheum Dis 2006; 65: 878-83.
4. RADNER H, NEOGI T, SMOLEN JS, ALETAHA D: Performance of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 2014; 73: 114-23.
5. BREEDVELD FC, WEISMAN MH, KAVAN-AUGH AF et al.: The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006; 54: 26-37.
6. SMOLEN JS, LANDEWé R, BREEDVELD FC et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69: 964-75.
7. HEIMANS L, WEVERS-de BOER KV, VISSER K et al.: A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study. Ann Rheum Dis 2014; 73: 1356-61.
8. RAMIRO S, RADNER H, van der HEIJDE D et al.: Combination therapy for pain management in inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis). Cochrane Database Syst Rev 2011 Oct 5; 10: CD008886.
9. RAMIRO S, GAUJOUX-VIALA C, NAM JL et al.: Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 2014; 73: 529-3.
10. KREMER JM, WEINBLATT ME, BANKHURST AD et al.: Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observations. Arthritis Rheum 2003; 48: 1493-9.
11. YAZICI Y, SOKKA T, KAUTIAINEN H, SWEARINGEN C, KULMAN I, PINCUS T: Long term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely the result of laboratory abnormalities. Ann Rheum Dis 2005; 64: 207-11.
12. WASKO MC, DASGUPTA A, HUBERT H, FRIES JF, WARD MM: Propensity-adjusted association of methotrexate with overall survival in rheumatoid arthritis. Arthritis Rheum 2013; 65: 334-42.
13. CHOI HK, HERNAN MA, SEEGER JD, ROBINS JM, WOLFE F: Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002; 359: 1173-7.
14. SARAUX A, DEVAUCHELLE-PENSEC V, ENGE-RRAN L, FLIPO RM: Most rheumatologists are conservative in active rheumatoid arthritis despite methotrexate therapy: results of the PRISME survey. J Rheumatol 2006; 33: 1258-65.
15. ALLAART CF, GOEKOOP-RUITERMAN YP, DE VRIES-BOUWSTRA JK, BREEDVELD FC, DIJKMANS BA, FARRarr study group: Aiming at low disease activity in rheumatoid arthritis with initial combination therapy or initial monotherapy strategies: the BeSt study. Clin Exp Rheumatol 2006; 24 (Suppl. 43): S,77-82.
16. WEVERS-de BOER K, VISSER K, HEIMANS L et al.: Remission induction therapy with methotrexate and prednisone in patients with early rheumatoid and undifferentiated arthritis (the IMPROVED study). Ann Rheum Dis 2012; 71: 1472-7.
17. VISSER K, KATCHAMART W, LOZA E et al.: Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 2009; 68: 1086-93.
18. DAHL MG, GREGORY MM, SCHEUER PJ: Methotrexate hepatotoxicity in psoriasis-comparison of different dose regimens. Br Med J 1972; 1: 654-6.
19. SHEA B, SWINDEN MV, TANJONG GHOGOMU E et al.: Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev 2013 May; 5: CD000951.
20. JOYCE DA, WILL RK, HOFFMAN DM, LAING B, BLACKBOURN SJ: Exacerbation of rheumatoid arthritis in patients treated with methotrexate after administration of folinic acid. Ann Rheum Dis 1991 Dec; 50: 913-4.
21. CHAN ES, CRONSTEIN BN: Methotrexate-how does it really work?. Nat Rev Rheumatol 2010; 6: 175-8.
22. CRONSTEIN B: How does methotrexate suppress inflammation?. Clin Exp Rheumatol 2010; 28 (Suppl. 61): S21-3.
23. MONTESINOS MC, DESAI A, CRONSTEIN BN: Suppression of inflammation by low-dose methotrexate is mediated by adenosine A2A receptor but not A3 receptor activation in thioglycollate-induced peritonitis. Arthritis Res Ther 2006; 8: R53.
24. NESHER G, MATES M, ZEVIN S: Effect of caffeine consumption on efficacy of methotrexate in rheumatoid arthritis. Arthritis Rheum 2003; 48: 571-2.
25. BENITO-GARCIA E, HELLER JE, CHIBNIK LB et al.: Dietary caffeine intake does not affect methotrexate efficacy in patients with rheumatoid arthritis. J Rheumatol 2006; 33: 1275-81.
26. VISSER K, van der HEIJDE D: Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis 2009; 68: 1094-9.
27. FURST DE, KOEHNKE R, BURMEISTER LF, KOHLER J, CARGILL I: Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. J Rheumatol 1989; 16: 313-20.
28. SCHNABEL A, REINHOLD-KELLER E, WILLMANN V, GROSS WL: Tolerability of methotrexate starting with 15 or 25 mg/week for rheumatoid arthritis. Rheumatol Int 1994; 14: 33-8.
29. VERSTAPPEN SM, JACOBS JW, van der VEEN MJ et al.: Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for " remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an" open-label strategy trial). Ann Rheum Dis 2007; 66: 1443-9.
30. LAMBERT CM, SANDHU S, LOCHHEAD A, HURST NP, McRORIE E, DHILLON V: Dose escalation of parenteral methotrexate in active rheumatoid arthritis that " has been unresponsive to conventional doses of methotrexate: a randomized," controlled trial. Arthritis Rheum 2004; 50: 364-71.
31. BRAUN J, KASTNER P, FLAXENBERG P et al.: Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: " results of a six-month, multicenter, randomized, double-blind, controlled, phase " IV trial. Arthritis Rheum 2008; 58: 73-81.
32. da COSTA SANTOS CM, de MATTOS PIMENTA CA, NOBRE MR: The PICO strategy for the research question construction and evidence search. Rev Lat Am Enfermagem 2007; 15: 508-11.
33. VISSER K, van der HEIJDE D: Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis 2009; 68: 1094-9.
34. MOHER D, LIBERATI A, TETZLAFF J, ALTMAN DG, PRISMA Group: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339: b2535.
35. MOUTERDE G, BAILLET A, GAUJOUX-VIALA C et al.: Optimizing methotrexate therapy in rheumatoid arthritis: a systematic literature review. Joint Bone Spine 2011; 78: 587-92.
36. THOMPSON RN, WATTS C, EDELMAN J, ESDAILE J, RUSSELL AS: A controlled two-centre trial of parenteral methotrexate therapy for refractory rheumatoid arthritis. J Rheumatol 1984; 11: 760-3.
37. ISLAM MS, HAQ SA, ISLAM MN et al.: Comparative efficacy of subcutaneous versus oral methotrexate in active rheumatoid arthritis. Mymensingh Med J 2013; 22: 483-8.
38. STAMP LK, BARCLAY ML, O'DONNELL JL et al.: Effects of changing from oral to subcutaneous methotrexate on red blood cell methotrexate polyglutamate concentrations and disease activity in patients with rheumatoid arthritis. J Rheumatol 2011; 38: 2540-7.
39. NG B, CHU A: Factors associated with methotrexate dosing and therapeutic decisions in veterans with rheumatoid arthritis. Clin Rheumatol 2014; 33: 21-30.
40. BAKKER MF, JACOBS JW, WELSING PM et al.: Are switches from oral to subcutaneous methotrexate or addition of ciclosporin to methotrexate useful steps in a tight control treatment strategy for rheumatoid arthritis?. A post hoc analysis of the CAMERA study. Ann Rheum Dis 2010; 69: 1849-52.
41. NG B, CHU A: Factors associated with methotrexate dosing and therapeutic decisions in veterans with rheumatoid arthritis. Clin Rheumatol 2014; 33: 21-30.
42. TUGWELL P, BENNETT K, BELL M, GENT M: Methotrexate in rheumatoid arthritis. Feedback on American College of Physicians guidelines. Ann Intern Med 1989; 110: 581-3.
43. TUGWELL P, BENNETT K, GENT M: Methotrexate in rheumatoid arthritis. Indications, contraindications, efficacy, and safety. Ann Intern Med 1987; 107: 358-66.
44. VERMEER M, KUPER HH, HOEKSTRA M et al.: Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study. Arthritis Rheum 2011; 63: 2865-72.
45. GABRIEL S, CREAGAN E, O'FALLON WM, JAQUITH J, BUNCH T: Treatment of rheumatoid arthritis with higher dose intravenous methotrexate. J Rheumatol 1990; 17: 460-5.
46. SHIROKY JB, NEVILLE C, SKELTON JD: High dose intravenous methotrexate for refractory rheumatoid arthritis. J Rheumatol 1992; 19: 247-51.
47. SCHIFF MH, JAFFE JS, FREUNDLICH B: Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses =15 mg may be overcome with subcutaneous administration. Ann Rheum Dis 2014; 73: 1549-51.
48. HOEKSTRA M, HAAGSMA C, NEEF C, PROOST J, KNUIF A, van de LAAR M: Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol 2004; 31: 645-8.
49. TUKOVA J, CHLADEK J, NEMCOVA D, CHLAD-KOVA J, DOLEZALOVA P: Methotrexate bioavailability after oral and subcutaneous dministration in children with juvenile idiopathic arthritis. Clin Exp Rheumatol 2009; 27: 1047-53.
50. GODFREY C, SWEENEY K, MILLER K, HAMILTON R, KREMER J: The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis. Br J Clin Pharmacol 1998; 46: 369-76.
51. HAZLEWOOD G, THORNE C, POPE J et al.: The comparative effectiveness of oral methotrexate versus subcutaneous methotrexate for the initial treatmend of early rheumatoid arthritis. Ann Rheum Dis 2013; 72: 246.
52. ALETAHA D, WARD MM, MACHOLD KP, NELL VP, STAMM T, SMOLEN JS: Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum 2005; 52: 2625-36.
53. ROZIN A, SCHAPIRA D, BALBIR-GURMAN A et al.: Relapse of rheumatoid arthritis after substitution of oral for parenteral administration of methotrexate. Ann Rheum Dis 2002; 61: 756-7.
54. HAMEED B, JONES H: Subcutaneous methotrexate is well tolerated and superior to oral methotrexate in the treatment of rheumatoid arthritis. Int J Rheum Dis 2010; 13: e83-4.
55. MAINMAN H, McCLAREN E, HEYCOCK C, SARAVANAN V, HAMILTON J, KELLY C: When should we use parenteral methotrexate?. Clin Rheumatol 2010; 29: 1093-8.
56. SCHIFF MH, JAFFE J, FREUNDLICH B: Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses =15 mg may be overcome with subcutaneous administration. Ann Rheum Dis 2014; 73: 1549-51.
57. PICHLMEIER U, HEUER K: Subcutaneous administration of methotrexate with a prefilled autoinjector pen results in a higher relative bioavailability compared to oral administration of methotrexate. Clin Exp Rheumatol 2014: 32: 563-71.
58. DERVIEUX T, ORENTAS LEIN D, MARCELLETTI J et al.: HPLC determination of erythrocyte methotrexate polyglutamates after low-dose methotrexate therapy in patients with rheumatoid arthritis. Clin Chem 2003; 49: 1632-41.
59. DERVIEUX T, GREENSTEIN N, KREMER J: Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. Arthritis Rheum 2006; 54: 3095-103.
60. DALRYMPLE JM, STAMP LK, O'DONNELL JL, CHAPMAN PT, ZHANG M, BARCLAY ML: Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2008; 58: 3299-308.
61. BAGGOTT JE, VAUGHN WH, HUDSON BB: Inhibition of 5-aminoimidazole-4-carboxamide ribotide transformylase, adenosine deaminase and 5'-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide. Biochem J 1986; 236: 193-200.
62. ALLEGRA CJ, DRAKE JC, JOLIVET J, CHABNER BA: Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc Natl Acad Sci USA 1985; 82: 4881-5.
63. de ROTTE MC, de JONG PH, PLUIJM SM et al.: Association of low baseline levels of erythrocyte folate with treatment nonresponse at three months in rheumatoid arthritis patients receiving methotrexate. Arthritis Rheum 2013; 65: 2803-13.
64. STAMP LK, O'DONNELL JL, CHAPMAN PT et al.: Methotrexate polyglutamate concentrations are not associated with disease control in rheumatoid arthritis patients receiving long-term methotrexate therapy. Arthritis Rheum 2010; 62: 359-68.
65. DALRYMPLE JM, STAMP LK, O'DONNELL JL, CHAPMAN PT, ZHANG M, BARCLAY ML: Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2008; 58: 3299-308.
66. OGUEY D, KOLLIKER F, GERBER NJ, REI-CHEN J: Effect of food on the bioavailability of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 1992; 35: 611-4.
67. BRINKER RR, RANGANATHAN P: Methotrexate pharmacogenetics in rheumatoid arthritis. Clin Exp Rheumatol 2010; 28 (Suppl. 61): S33-9.
68. RANGANATHAN P: ABC transporter genes and methotrexate response in rheumatoid arthritis. J Rheumatol 2013; 40: 536.
69. HUGHES LB, BEASLEY TM, PATEL H et al.: Racial or ethnic differences in allele frequencies of single-nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritis. Ann Rheum Dis 2006; 65: 1213-8.
70. FISHER MC, CRONSTEIN BN: Metaanalysis of methylenetetrahydrofolate reductase (MTHFR) polymorphisms affecting methotrexate toxicity. J Rheumatol 2009; 36: 539-45.
71. KUNG TN, DENNIS J, MA Y et al.: RFC-1 80G>A is a genetic determinant of methotrexate efficacy in rheumatoid arthritis: a Human genome review and meta-analysis of observational studies. Arthritis Rheum 2014; 66: 1111-20.
72. PENG Z, FERNANDEZ P, WILDER T et al.: Ecto-5'-nucleotidase (CD73)-mediated extracellular adenosine production plays a critical role in hepatic fibrosis. Nucleosides Nucleotides Nucleic Acids 2008; 27: 821-4.
73. PENG Z, BOREA PA, VARANI K et al.: Adenosine signaling contributes to ethanol-induced fatty liver in mice. J Clin Invest 2009; 119: 582-94.
74. KREMER JM, ALARCON GS, WEINBLATT ME et al.: Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum 1997; 40: 1829-37.
75. McKENDRY RJ, DALE P: Adverse effects of low dose methotrexate therapy in rheumatoid arthritis. J Rheumatol 1993; 20: 1850-6.
76. WEINBLATT ME, MAIER AL, COBLYN JS: Low dose leucovorin does not interfere with the efficacy of methotrexate in rheumatoid arthritis: an 8 week randomized placebo controlled trial. J Rheumatol 1993; 20: 950-2.
77. van EDE AE, LAAN RF, ROOD MJ et al.: Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2001; 44: 1515-24.
78. FATHI NH, MITROS F, HOFFMAN J et al.: Longitudinal measurement of methotrexate liver concentrations does not correlate with liver damage, clinical efficacy, or toxicity during a 3.5 year double blind study in rheumatoid arthritis. J Rheumatol 2002; 29: 2092-8.
79. SALLIOT C, van der HEIJDE D: Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 2009; 68: 1100-4.
80. VISSER K, van der HEIJDE DM: Risk and management of liver toxicity during methotrexate treatment in rheumatoid and psoriatic arthritis: a systematic review of the literature. Clin Exp Rheumatol 2009; 27: 1017-25.
81. VISSER K, KATCHAMART W, LOZA E et al.: Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 2009; 68: 1086-93.
82. KUITUNEN T, MALMSTROM J, PALVA E, PETTERSSON T: Pancytopenia induced by low-dose methotrexate. A study of the cases reported to the Finnish Adverse Drug Reaction Register From 1991 to 1999. Scand J Rheumatol 2005; 34: 238-41.